Attovia Therapeutics raises $289.0M IPO (United States, Aug 2026)
Reach the investors backing rounds like this
Backed by Goldman Sachs, Qiming Venture Partners · verified emails and LinkedIn on Datapile
Immunotherapy Startup Attovia Lists on Nasdaq: IPO Raises $289 Million, First-Day Market Cap Tops $900 Million - finance.biggo.com
Attovia Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for immune-mediated diseases. The company holds an exclusive global license to the ATTOBODY biologics platform, which enables the rapid generation of diverse candidate molecules. Attovia has already nominated three product candidates and aims to advance their clinical development with proceeds from their recent IPO.
Immunotherapy Startup Attovia Lists on Nasdaq: IPO Raises $289 Million, First-Day Market Cap Tops $900 Million finance.biggo.com
| Oct 02, 2026 | Supabase | $150.0M | Growth Equity | United States |
| Oct 02, 2026 | SoLa Impact | $93.0M | Debt | United States |
| Oct 02, 2026 | FieldAI | $700.0M | — | United States |
| Oct 02, 2026 | CScale | $145.0M | Series C | United States |
21,703 investors back startups in United States
You just read who funded Attovia Therapeutics. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.